TG Therapeutics, Inc. (TGTX)

27.43
0.20 0.73
NASDAQ
Prev Close 27.23
Open 27.27
Day Low/High 27.08 / 28.25
52 Wk Low/High 5.49 / 31.97
Volume 1.18M
Exchange NASDAQ
Shares Outstanding 126.65B
Market Cap 3.81B
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

2 Candidates to Consider as Biotech Buyout Activity Picks Up

2 Candidates to Consider as Biotech Buyout Activity Picks Up

A handful of deals have been announced this week alone and they give rise to expectations of more acquisitions to come.

It's Options Expiration Day, and I'm Cashing In

It's Options Expiration Day, and I'm Cashing In

Covered call options provide downside protection for holders of the underlying stock and can yield nice profits, too.

Here's a Quartet of Small Biotechs That Could Make for Acquisition Targets

Here's a Quartet of Small Biotechs That Could Make for Acquisition Targets

Merger activity is picking up this week in the biotechnology sector and these four promising companies would be good buyout candidates.

These Biotech Stocks Caught My Attention

Trade continues to be listless and in a relatively tight trading range as markets try to end a solid week for investors. Equities are pretty flat across the board. I would not be surprised to see some profit taking later in the day. Cashing in some ...

Earnings Continue to Show Solid Results

Pre-market futures are still pointing to a slightly up open as we try to end the trading week hitting more all-time highs. Fourth quarter earnings results continue to flow across the wires. Big financial firms have kicked off the earnings season thi...

Why I Like Using Buy-Writes in the Biotech Sector

Why I Like Using Buy-Writes in the Biotech Sector

Putting buy-writes in your investing 'toolbox' seems one route to becoming a better investor in 2020.

3 Small-Cap Biotech Stocks That Could Thrive in 2020

3 Small-Cap Biotech Stocks That Could Thrive in 2020

The trio of BioDelivery Sciences, Omeros and TG Therapeutics looks well-positioned to capitalize on their potential in the New Year.

2 Potential Targets as Biotech Acquisition Activity Heats Up

2 Potential Targets as Biotech Acquisition Activity Heats Up

TG Therapeutics and Exelixis could find themselves on the shopping lists of other companies.

2 Small Biotech Stocks Spurt Ahead on Positive Developments

2 Small Biotech Stocks Spurt Ahead on Positive Developments

Heron Therapeutics and TG Therapeutics each gave investors reasons for cheer in the last few days.

TG Therapeutics May Have Potential but the Charts Need More Work

TG Therapeutics May Have Potential but the Charts Need More Work

Shares of this biotech company are up 75% for 2019, despite recent weakness.

3 Promising Small Biotech Stocks to Watch

3 Promising Small Biotech Stocks to Watch

I think there is still upside left in a variety of smaller names especially if M&A activity picks up across the industry.

Keep Your Eye on the Oncology Sector Among Biotech Stocks

Keep Your Eye on the Oncology Sector Among Biotech Stocks

The myriad names in oncology have been the hottest area for acquisitions along with gene therapy.

Celebrating the Greatness of Individual Traders

Celebrating the Greatness of Individual Traders

Good individual traders will produce returns far in excess of anything that traditional Wall Street will earn.

3 Recent Big Gainers Kick Off the Dramatic Return of 'Small-Cap Friday'

3 Recent Big Gainers Kick Off the Dramatic Return of 'Small-Cap Friday'

Small-caps have done better than their bigger brethren so far in 2019, and these three stocks are a reason why.

How I See Biotechs Now

How I See Biotechs Now

I expect deal volume to have a substantial uptick before the end of 2018 rolls around.

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside

The biotech sector has seen a big rally, but there are still opportunities.

Biotech M&A: Who's Next After Gilead-Kite?

Biotech M&A: Who's Next After Gilead-Kite?

Prospects for acquisition activity in the sector are improving.

Biotech Needs a Shot in the Arm

Biotech Needs a Shot in the Arm

But there is hope, as the FDA has approved almost as many new compounds in 2017 as in all of 2016.

The Machines Are Sapping the Fun out of This Day

The Machines Are Sapping the Fun out of This Day

Historically, the day before a holiday often has a positive bias, but the algos have killed emotion.

Biotech Needs a Shot in the Arm

Biotech Needs a Shot in the Arm

But there is hope, as the FDA has approved almost as many new compounds in 2017 as in all of 2016.

Shark Bites: There Wasn't Even a Dip to Buy

Shark Bites: There Wasn't Even a Dip to Buy

Action runs counter to pattern, leaving market players wondering what to do.

Don't Be Surprised If Dip Buyers Jump In on Any Pullback

Don't Be Surprised If Dip Buyers Jump In on Any Pullback

We'll see what happens in the way of reaction to Trump's tax policy this afternoon, but if we sell off I'm likely going to be a buyer.

Desire to Add Exposure Leads Indices Higher

Desire to Add Exposure Leads Indices Higher

The fact that many traders weren't well-positioned for Monday's move up is helping to create one-way action this morning.

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Nine biotech and drug companies want FDA approval, but need changed standards to get it.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

2 Biotechs to Watch Ahead of the Election

2 Biotechs to Watch Ahead of the Election

These 2 small-caps have strong pipelines and are becoming analyst darlings.

TG Therapeutics Looks Like a Healthy Play

TG Therapeutics Looks Like a Healthy Play

Small biotech tanked on weak earnings, but still seems promising.